Compositions, systems, and methods targeting gasdermin e

Abstract

Described herein are compositions, pharmaceutical compositions, methods, and kits relating to knocking down, inhibiting, or otherwise reducing the activity and/or expression of Gasdermin E. Methods as described herein can be indicated, for example, in subjects having or suspected of having, for example, Traumatic Optic Neuropathy (TON), Glaucoma, juvenile glaucoma, Leber's Hereditary Optic Neuropathy, Optic Neuritis, Ischemic Optic Neuropathy, Diabetic Retinopathy, Retinal Occlusion, Anterior Ischemic Optic Neuropathy (AION), Infectious Neuropathies, Neuromyelitis optica (NMO), Behçet's disease, optic nerve hypoplasia, Central or branch retinal artery occlusion (CRAO, BRAO), Radiation Optic Neuropathy, Optic nerve glioma, Age-related macular degeneration (AMD).

Dependencies are inferred from the claim text.